LCTX

Lineage is a pre-commercial cell-therapy developer, and its financials read exactly like one: $14.6M of FY2025 revenue that is really collaboration and milestone income (tied to the Roche/Genentech OpRegen deal), not durable product sales. The history proves the point — revenue has whipsawed from $4.34M (2021) to $14.7M (2022) to $8.95M (2023) to $9.50M (2024) to $14.6M (2025), so the headline +53.2% growth is noise, not a trend. At a $336M market cap the stock trades at 23.1x that revenue, a multiple that only makes sense as a bet on the pipeline, not the P&L. Losses are structural: operating margin -251.6%, net margin -436.5%, ROE -142.6%, and a $467M accumulated deficit.

The reported -$63.5M net loss (241% worse YoY) overstates the cash story — operating cash burn was only -$18.9M and actually improved 18.1%, so the gap is largely non-cash, consistent with the +91.2% jump in total liabilities to $69.2M (likely warrant/derivative remeasurement). Near-term liquidity is genuinely fine: $40.8M cash and current assets of $59.2M against just $11.4M current liabilities (a ~5x current ratio), giving roughly two years of runway. But R&D is ramping (+42.2% to $17.7M), shares already diluted +9.1%, and a clinical-stage burn structure means more raises are coming — equity has already fallen 43.2% to $44.5M.